Phase 3 Readout~month

Phase 3 Topline: Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Wit

Indication
Breast Cancer

Other upcoming events for RLAY

Patent ExpiryPatent/Exclusivity Expiry: GILOTRIF
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Ve
Patent ExpiryPatent/Exclusivity Expiry: ALIQOPA
Patent ExpiryPatent/Exclusivity Expiry: TAFINLAR
Patent ExpiryPatent/Exclusivity Expiry: AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Wit — RLAY Phase 3 Readout | BioSniper